What is Illumina?

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. (source)

Illumina Employee Count

Number of Illumina employees:

7,700 employees

Last updated 1/1/20

---

Illumina Revenue Totals

Illumina annual revenue:

• 2021: $4.526 billion
• 2020: $3.239 billion
• 2019: $3.543 billion
• 2018: $3.333 billion
• 2017: $2.752 billion
• 2016: $2.398 billion
• 2015: $2.220 billion

---

Illumina annual net income:

• 2021: $762 million
• 2020: $656 million
• 2019: $990 million
• 2018: $782 million
• 2017: $678 million
• 2016: $428 million
• 2015: $458 million

---

Additional Illumina Statistics

Number of Illumina patents:

799 issued US patents and 617 pending US patent applications

Last updated 1/16/20

---

Recent Illumina News

• Illumina Enters Co-Development Partnership with SomaLogic, 01/05/2022
• Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care, 01/12/2022
• Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership, 01/12/2022
• Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference, 01/12/2022
• Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer, 02/03/2022
• Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021, 02/10/2022

---

Please note that some of these numbers are easier to find than others. A few of these Illumina stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.

Related Categories:

Related Tags: